The importance of diabetic nephropathy in current nephrological practice

Nephrology Dialysis Transplantation

Volumn 18, Issue 9, 2003, Pages 1716-1725

  Locatelli, Francesco ^a   Canaud, Bernard ^b   Eckardt, Kai Uwe ^c   Stenvinkel, Peter ^d   Wanner, Christoph ^e   Zoccali, Carmine ^f  

^a A MANZONI HOSPITAL   (Italy)

^b LAPEYRONIE HOSPITAL   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f CNR   (Italy)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Glycosaminoglycans; Microalbuminuria; Oxidative stress; Prevention; Treatment

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ARGIPRESSIN; ATENOLOL; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ENALAPRIL; GLUCOSE; GLYCOSAMINOGLYCAN; HEMOGLOBIN A1C; INSULIN; IRBESARTAN; N(G) NITROARGININE METHYL ESTER; NISOLDIPINE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PROTEIN KINASE C INHIBITOR; PROTEOHEPARAN SULFATE; REACTIVE OXYGEN METABOLITE; RENIN; SODIUM; UNINDEXED DRUG;

AWARENESS; BLOOD PRESSURE REGULATION; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG CLASSIFICATION; DRUG EFFICACY; EXERCISE; GLUCOSE BLOOD LEVEL; HEREDITY; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LIFESTYLE; MEDICAL PRACTICE; METABOLIC DISORDER; MICROALBUMINURIA; MORTALITY; NEPHROLOGY; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SECONDARY PREVENTION; SMOKING CESSATION; SODIUM RETENTION; SURVIVAL; TREATMENT PLANNING;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GLYCOSAMINOGLYCANS; GLYCOSYLATION END PRODUCTS, ADVANCED; HEALTH BEHAVIOR; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MICROCIRCULATION; OXIDATIVE STRESS;

EID: 0041883730     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg288     Document Type: Review

References (66)

1. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
2. McCarty D, Zimmet P. Diabetes 1994 to 2010: global estimates and projections. Leverkusen: Bayer AG, 1994; 1-46
3. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996; 156: 286-328
4. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21; 597-603
5. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23:B54-B64
6. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713-720
7. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306-1309
8. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann Intern Med 2001; 134: 370-379
9. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870-878
10. Fioretto P, Steffes MW, Sutherland DER et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75
11. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462
12. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
13. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
14. Feldt-Rasmussen B, Mathiesen ER, Deckert T, Christensen NJ, Bent-Hansen L, Nielsen MD. Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in Type-1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 610-617
15. Roland JM, O'Hare JP, Walters G, Corral RJM. Sodium retention in response to saline infusion in uncomplicated diabetes mellitus. Diabetes Res 1986; 3: 213-215
16. Stenvinkel P, Saggar-Malik AK, Wahrenberg H, Diczfalusy U, Bolinder J, Alvestrand A. Impaired intrarenal dopamine production following intravenous sodium chloride infusion in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 114-118
17. Lee MR. Dopamine and the kidney: ten years on. Clin Sci 1993; 84: 357-375
18. Rudberg S, Lemne C, Persson B, Krekula A, deFaire U, Aperia A. The dopaminergic response to high salt diet in insulin-dependent diabetes mellitus and in family history of hypertension. Pediat Nephrol 1997; 11: 169-173
19. Tsuchida H, Imai G, Shima Y, Satoh T, Owada S. Mechanisms of sodium load-induced hypertension in non-insulin dependent diabetes mellitus model rats: defective dopaminergic system to inhibit Na-K-ATPase activity in renal epithelial cells. Hypertens Res 2001; 24: 127-135
20. Stenvinkel P, Bolinder J, Alvestrand A. Effects of insulin on renal haemodynamics and the proximal and distal tubular sodium handling in healthy subjects. Diabetologia 1992; 35: 1042-1048
21. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A. Renal haemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidaemia. J Am Soc Nephrol 1995; 5: 1-10
22. Ter Maaten JC, Bakker SJL, Serne EH, Moshage HJ, Donker AJM, Gans ROB. Insulin-mediated increases in renal plasma flow are impaired in insulin-resistant normal subjects. Eur J Clin Invest 2000; 30: 1090-1098
23. Molinari C, Battaglia A, Bona G et al. Mechanisms of the renal vasodilation caused by insulin in anesthetized pigs. Life Sci 2001; 69: 1699-1708
24. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent. J Am Coll Cardiol 1999; 33: 1506-1511.
25. Stenvinkel P, Bolinder J, Alvestrand A. Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in Type-1 diabetic patients having incipient nephropathy. Acta Diabetologia 1997; 34: 10-17
26. Vallon V, Blantz RC and Scott T. Glomerular hyperfiltration and the salt paradox in early type 1 diabetes mellitus: a tubulocentric view. J Am Soc Nephrol 2003; 14: 530-537
27. Hannedouche TP, Delgrado AG, Gnoinsahe DA, Boitard C, Gruenfeld JP. Renal hemodynamics and segmental tubular sodium reabsorption in early type 1 diabetes. Kidney Int 1990; 37: 1126-1133
28. Vallon V, Huang DY, Deng A, Richter K, Blantz RC, Thomson S. Salt-sensitivity of proximal reabsorption alters macula densa salt and explains the paradoxical effect of dietary salt on glomerular filtration rate in diabetes mellitus. J Am Soc Nephrol 2002; 13: 1865-1871
29. Miller JA. Renal response to sodium restriction in patients with early diabetes mellitus. J Am Soc Nephrol 1997; 8: 749-755
30. Vallon V, Wead LM, Blantz RC. Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: effect of sodium and salt restriction. J Am Soc Nephrol 1995; 5: 1761-1767
31. American Diabetes Association. Position statement: nutrition recommendations and principles for people with diabetes mellitus. Diabetes Care 1998; 21: S32-S35
32. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 438-443
33. McGill MJ, Donnelly R, Molyneaux L, Yue DK. Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM. Diabetes Res Clin Pract 1996; 33: 173-179
34. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321: 1074-1079
35. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165
36. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 1993; 21: 387-393
37. Schmidt S, Ritz E. Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant 1997;12 [Suppl 2]: 37-41
38. Schmidt S, Strojek K, Grzeszczak W, Bergis K, Ritz E. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 1997; 12: 427-429
39. Schmidt S, Giessel R, Bergis KH et al. Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 1996; 11: 1755-1761
40. Rogus JJ, Moczulski D, Freire MB, Yang Y, Warram JH, Krolewski AS. Diabetic nephropathy is associated with AGT polymorphism T235: results of a family-based study. Hypertension 1998; 31: 627-631
41. Lindner T, Wanner C, Berger M. Genetic aspects of diabetic nephropathy. Kidney Int 2003; 84 [Suppl]: S186-S191
42. Bingham C, Bulman MP, Ellard S et al. Mutations in the hepatocyte nuclear factor-1beta gene are associated with familial hypoplastic glomerulocystic kidney disease. Am J Hum Genet 2001; 68: 219-224
43. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet 2000; 8: 2001-2008
44. Bowden DW, Sale M, Howard TD et al. Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 1997; 46: 882-886
45. Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes 1998; 47: 1164-1169
46. Yu H, Bowden DW, Spray BJ, Rich SS, Freedman BI. Linkage analysis between loci in the renin-angiotensin axis and endstage renal disease in African Americans. J Am Soc Nephrol 1996; 7: 2559-2564
47. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998; 47: 821-830
48. Solini A, Giacchetti G, Sfriso A et al. Polymorphisms of angiotensin-converting enzyme and angiotensinogen genes in type 2 diabetic sibships in relation to albumin excretion rate. Am J Kidney Dis 1999; 34: 1002-1009
49. Adler SG, Pahl M, Seldin MF. Deciphering diabetic nephropathy: progress using genetic strategies. Curr Opin Nephrol Hypertens 2000; 9: 99-106
50. Vardarli I, Baier LJ, Hanson RL et al. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002; 62: 2176-2183
51. Holmes DI, Wahab NA, Mason RM. Cloning and characterization of ZNF236, a glucose-related Kruppel-like zinc-finger gene mapping to human chromosome 18q22-q23. Genomics 1999; 60: 105-109
52. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226
53. Raats CJI, van den Born J, Berden JHM. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000;57:385-400
54. Rosenberg RD, Shwornak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate proteoglycans of the cardiovascular system: Specific structures emerge but is synthesis regulated ? J Clin Invest 1997; 100: S67-S75
55. Goligorski MS, Chen J, Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy. Hypertension 2001; 37: 744-748
56. Parving HH, Nielsen FS, Bang LE et al. Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy. Diabetologia 1996; 39: 1590-1597
57. Gambaro G, van der Woude FJ. Glycosaminoglycans: use in treatment of diabetic nephropathy. J Am Soc Nephrol 2000; 11: 359-368
58. Van der Pijl JW, van der Woude FJ, Swart W, van Es LA, Lemkes HHPJ. Effect of danaparoid sodium on hard exsudates in diabetic retinopathy. Lancet 1997; 350: 1743-1745
59. Schinzel R, Münch G, Heidland A. Advanced glycation end products in end-stage renal disease and their removal. Nephron 2001; 87: 295-303
60. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int 2000; 58 [Suppl 77]: S3-S12
61. Horie K, Miyata T, Maeda K et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997; 100: 2995-3004
62. Suzuki D, Miyata T, Saotome N et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999; 10: 822-832
63. Chandra A, Srivastava S, Petrash JM, Bhatnagar A, Srivastava SK. Active site modification of aldose reductase by nitric oxide donors. Biochim Biophys Acta 1997; 131: 217-222
64. Maxwell SR. Coronary artery disease-free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol 2000; 95 [Suppl]: S65-S71
65. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int 2000; 58 [Suppl 77]: S3-S12
66. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27: 535-542